What changed from existing technology?
This study describes a way to create virtual patients that better match real diabetes patients, helping to test and improve diabetes treatments.
The method uses routine clinical data to create more diverse and representative virtual patient cohorts compared to previous approaches that relied on limited or non-representative data.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
proach for creating virtual patient cohorts reflecting real-world diabetes treatment outcomes. Virtual patients (VPs) are widely used to evaluate the performanc
Title ↗A methodological approach for creating virtual patient cohorts reflecting real-world diabetes treatment outcomes. Virtual patients (VPs) are widely u
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This approach could be used to improve the development and evaluation of diabetes management strategies by providing more realistic virtual patient models for testing.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.